116 related articles for article (PubMed ID: 36610939)
1. The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients.
Liu H; Nassour I; Lebowitz S; D'Alesio M; Hampton E; Desilva A; Hammad A; AlMasri S; Khachfe HH; Singhi A; Bahary N; Lee K; Zureikat A; Paniccia A
HPB (Oxford); 2023 Mar; 25(3):320-329. PubMed ID: 36610939
[TBL] [Abstract][Full Text] [Related]
2. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma.
Liu H; Naxerova K; Pinter M; Incio J; Lee H; Shigeta K; Ho WW; Crain JA; Jacobson A; Michelakos T; Dias-Santos D; Zanconato A; Hong TS; Clark JW; Murphy JE; Ryan DP; Deshpande V; Lillemoe KD; Fernandez-Del Castillo C; Downes M; Evans RM; Michaelson J; Ferrone CR; Boucher Y; Jain RK
Clin Cancer Res; 2017 Oct; 23(19):5959-5969. PubMed ID: 28600474
[No Abstract] [Full Text] [Related]
3. Correlation between Angiotensin Inhibitor Administration and Longer Survival in Patients Who Underwent Curative Resection for Pancreatic Cancer.
Yang HY; Kang MY; Kang CM; Lee WJ; Hwang HK
Yonsei Med J; 2024 Jun; 65(6):324-331. PubMed ID: 38804026
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Renin-Angiotensin System Inhibitors in Patients Undergoing Pancreatic Cancer Resection.
Abe S; Nakai Y; Arita J; Ichida A; Kawaguchi Y; Akamatsu N; Kaneko J; Ijichi H; Koike K; Fujishiro M; Hasegawa K
Pancreas; 2024 Mar; 53(3):e233-e239. PubMed ID: 38227640
[TBL] [Abstract][Full Text] [Related]
5. Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma.
Gong Y; Fan Z; Luo G; Huang Q; Qian Y; Cheng H; Jin K; Ni Q; Yu X; Liu C
Pancreatology; 2020 Jun; 20(4):716-721. PubMed ID: 32249060
[TBL] [Abstract][Full Text] [Related]
6. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.
Serrano PE; Cleary SP; Dhani N; Kim PT; Greig PD; Leung K; Moulton CA; Gallinger S; Wei AC
Ann Surg Oncol; 2015 Apr; 22(4):1160-7. PubMed ID: 25348784
[TBL] [Abstract][Full Text] [Related]
7. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis.
Kamarajah SK; Sonnenday CJ; Cho CS; Frankel TL; Bednar F; Lawrence TS; Nathan H
Ann Surg; 2021 Mar; 273(3):587-594. PubMed ID: 30817352
[TBL] [Abstract][Full Text] [Related]
8. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
[TBL] [Abstract][Full Text] [Related]
9. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
[TBL] [Abstract][Full Text] [Related]
10. Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma - A Swedish nationwide register-based study.
Holmberg M; Radkiewicz C; Strömberg C; Öman M; Ghorbani P; Löhr JM; Sparrelid E
Pancreatology; 2023 Jan; 23(1):90-97. PubMed ID: 36522260
[TBL] [Abstract][Full Text] [Related]
11. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients.
Park JY; King J; Reber H; Joe Hines O; Mederos MA; Wang HL; Dawson D; Wainberg Z; Donahue T; Girgis M
J Surg Oncol; 2021 Feb; 123(2):389-398. PubMed ID: 33146409
[TBL] [Abstract][Full Text] [Related]
12. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
Golan T; Sella T; O'Reilly EM; Katz MH; Epelbaum R; Kelsen DP; Borgida A; Maynard H; Kindler H; Friedmen E; Javle M; Gallinger S
Br J Cancer; 2017 Mar; 116(6):697-702. PubMed ID: 28183138
[TBL] [Abstract][Full Text] [Related]
13. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
[TBL] [Abstract][Full Text] [Related]
14. Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I-II or unresected stage III pancreatic cancer.
Ma SJ; Iovoli AJ; Hermann GM; Prezzano KM; Singh AK
Cancer Med; 2019 Aug; 8(9):4110-4123. PubMed ID: 31183965
[TBL] [Abstract][Full Text] [Related]
15. [Surgical therapy of pancreatic cancer - 5 years survival].
Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R
Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155
[TBL] [Abstract][Full Text] [Related]
16. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma.
Mehtsun WT; McCleary NJ; Maduekwe UN; Wolpin BM; Schrag D; Wang J
JAMA Oncol; 2022 Jan; 8(1):88-95. PubMed ID: 34854874
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Effect of Age in Resected Pancreatic Cancer Patients: A Propensity Score Matching Analysis.
Xu Y; Zhang Y; Han S; Jin D; Xu X; Kuang T; Wu W; Wang D; Lou W
Front Oncol; 2022; 12():789351. PubMed ID: 35433408
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and surgical outcomes of resectable acinar cell carcinoma of the pancreas-propensity score matching analysis with pancreatic ductal adenocarcinoma.
Chen H; Xu Z; Shen Z; Weng Y; Wang W; Ying X; Wang X; Deng X; Shen B
Eur J Surg Oncol; 2022 May; 48(5):1062-1067. PubMed ID: 34887166
[TBL] [Abstract][Full Text] [Related]
20. The Main Bottleneck for Non-Metastatic Pancreatic Adenocarcinoma in Past Decades: A Population-Based Analysis.
Li Y; Liu W; Zhao L; Xu Y; Yan T; Yang Q; Pei Q; Güngör C
Med Sci Monit; 2020 May; 26():e921515. PubMed ID: 32358953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
